This article is more than 5 years old. Information may no longer be current.

Imprimis reports $2.5 million net loss in third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Imprimis Pharmaceuticals reported a net loss of $2.5 million, or $0.27 per common share, in the third quarter, compared with a loss of $2.1 million, or $0.23 per common share, in the third quarter of last year, according to a press release.

Total revenues were $0.4 million in the third quarter, an increase from $2,500 in total revenues the year before.

Approximately $149,000 of revenues were related to sales of the Imprimis’ Dropless formulations, a 190% increase from $51,000 in revenues in the second quarter.